ORCID "0000-0001-7934-7039" Makale Koleksiyonu için listeleme
-
Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: Single center experience from Turkey
Açıkgöz, Özgür; Yıldız, Anıl; Bilici, Ahmet; Ölmez, Ömer Fatih; Basım, Pelin; Çakır, Aslı (Lippincott Williams and Wilkins, 2022)The aim of this study was to investigate the predictive value of PLR and NLR as an indicator of pathological complete response (pCR) in patients with breast cancer after NACT. One hundred thirty-nine patients with early ... -
The prevalence of drug-drug interactions and reported therapy related side-effects in oncology out-patients
Umar, Rashida Muhammad; Can, Zeynep Yeşim; Güven Eke, Ece; Karataş Koçberber, Emine; Ölmez, Ömer Fatih (Marmara University, 2023)Objective: The use of multiple medications in cancer patients is unavoidable; thus, adverse drug-drug interactions are frequent. This study aims to assess the prevalence of potential drug interactions in oncology patients ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin; Artaç, Mehmet (Springer Japan KK, 2021)Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
Yıldız, Anıl; Bilici, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Basım, Pelin; Çakır, Tansel; Çakır, Aslı; Ölmez, Ömer Fatih; Gezen, Cem; Yıldız, Özcan (Taylor and Francis Ltd., 2024)The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to ... -
Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey
Çakan, Burçin; Açıkgöz, Özgür; Bilici, Ahmet; Demir, Tarık; Öven, Bala Başak; Hamdard, Jamshid; Olmuşçelik, Oktay; Ölmez, Ömer Fatih; Şeker, Mesut; Yıldız, Özcan (Zerbinis Publications, 2021)Purpose: The purpose of this study was to investigate the prognostic value,and the effect of primary tumor location on targeted therapy selection in patients with metastatic colorectal cancer (mCRC). Methods: A total of ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Açıkgöz, Özgür; Kutlu, Yasin; Bilici, Ahmet; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Ankara Society of Hematology and Oncology, 2021)Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ... -
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
Erol, Vedat Buğra; Göktaş Aydın, Sabin; Bilici, Ahmet; Çakır, Aslı; Açıkgöz, Özgür; Ölmez, Ömer Fatih; Basım, Pelin (Taylor and Francis Ltd., 2023)To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ... -
Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
Tural, Deniz; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Erman, Mustafa; Coşkun, Hasan Şenol; Artaç, Mehmet; Kılıçkap, Saadettin (Springer, 2022)Background Atezolizumab (ATZ) has demonstrated antitumor activity in previous studies in patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of ATZ was modest. Therefore, finding ... -
The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Ölmez, Ömer Fatih; Öven, Bala Başak; Açıkgöz, Özgür; Çakır, Tansel; Basım, Pelin; Çakır, Aslı; Kutlu, Yasin; Hamdard, Jamshid (Karger, 2022)Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy ... -
Survival effect of palliative radiotherapy in patients with metastatic castration-resistant prostate cancer developing oligo-progression under antiandrogen treatment
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Açıkgöz, Özgür; Aydın, Ahmet; Bilici, Ahmet; Ölmez, Ömer Fatih; Ünal, Dilek; Karcı, Ebru; Yıldız, Özcan (Istanbul University, 2023)Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This ... -
Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: A multicenter analysis
Açıkgöz, Özgür; Bilici, Ahmet; Tataroğlu Özyükseler, Deniz; Göktaş Aydin, Sabin; Selçukbiricik, Fatih; Rzazade, Rashad; Ölmez, Ömer Fatih; Başak Çağlar, Hale (Turkiye Klinikleri, 2023)Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease ...